GSK PLC Sponsored ADR (GSK)
(Delayed Data from NYSE)
$39.16 USD
+0.26 (0.67%)
Updated Jul 12, 2024 03:59 PM ET
After-Market: $39.16 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
A Value C Growth B Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$39.16 USD
+0.26 (0.67%)
Updated Jul 12, 2024 03:59 PM ET
After-Market: $39.16 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
A Value C Growth B Momentum A VGM
Zacks News
Zacks Market Edge Highlights: Exxon, Diageo, GlaxoSmithKline, Micron and AMN
by Zacks Equity Research
Zacks Market Edge Highlights: Exxon, Diageo, GlaxoSmithKline, Micron and AMN
J&J (JNJ) to Begin Pharma Q1 Earnings: What's in Store?
by Zacks Equity Research
The positive trend seen in J&J's (JNJ) pharma segment sales in the second half of 2017 is likely to continue in Q1.
Pfizer's Kidney Cancer Drug Misses Endpoint in Phase III
by Zacks Equity Research
Pfizer's (PFE) kidney cancer drug Inlyta (axitinib) fails to demonstrate a clear improvement in the primary endpoint of extending disease-free survival (DFS) in a late-stage study.
What All Investors Should Know about Trade Deficits and Recessions
by Tracey Ryniec
What's the trade deficit really about? And what are the key signals that may alert investors to an upcoming recession?
Merck's Keytruda Offers Survival Benefit in Lung Cancer Study
by Zacks Equity Research
Merck's (MRK) phase III study showed that Keytruda monotherapy led to significantly improved overall survival (OS) as a first-line therapy in certain lung cancer patients.
4 Drug/Biotech Stocks to Buy Ahead of World Health Day
by Indrajit Bandyopadhyay
Given the increase in population and incidence of diseases along with growing awareness and healthcare coverage initiatives, the drug sector is expected to grow.
Novartis Announces Data on Cardiovascular Drug Entresto
by Zacks Equity Research
Novartis AG (NVS) announces encouraging results from the PARADIGM-HF trial on cardiovascular drug Entresto in JAMA Cardiology wherein it was observed Entresto significantly improved seven out of 10 types of physical and social activities at eight months.
Lilly's Cyramza Shows Survival Benefit in Liver Cancer Study
by Zacks Equity Research
A late-stage study evaluating Eli Lilly's (LLY) Cyramza for the second-line treatment of liver cancer patients shows that such patients derived a survival benefit with Cyramza after first-line treatment with Nexavar.
GlaxoSmithKline's Horlicks Up for Grabs: Who Will Snap It Up?
by Zacks Equity Research
As GlaxoSmithKline (GSK) starts a strategic review of Horlicks and other smaller nutrition products, a number of companies in the food & beverage industry are waiting to scoop it up.
Puma's Shares Fall This Year Post a Solid 2017: Here's Why
by Zacks Equity Research
Although the FDA approval for Puma's (PBYI) Nerlynx along with strategic alliances appreciates the stock in 2017, the CHMP's negative opinion on the cancer drug in 2018 affects its share price.
Company News For Mar 28, 2018
by Zacks Equity Research
Companies in the news are: RHT,MKC,INFO,GSK,NVS
Glaxo (GSK) Buys Novartis' Stake in Consumer Healthcare JV
by Zacks Equity Research
Glaxo (GSK) is buying out Novartis' stake in their Consumer Healthcare JV. Glaxo is also initiating a strategic review of its Horlicks business and its majority stake in Indian subsidiary.
4 Top-Ranked Drug/Biotech Stocks to Buy as Q1 Nears End
by Kinjel Shah
The first quarter of 2018 is drawing to a close. With the outlook optimistic for the rest of the year, we highlight four drug/biotech stocks worth buying
Pfizer's Chantix Fails in Phase IV Study in Young Smokers
by Zacks Equity Research
Pfizer's (PFE) Chantix fails to meet primary endpoint in a phase IV study, a regulatory post-marketing commitment.
Glaxo Drops Bid for Pfizer Unit, Shingrix Gains EU/Japan Nod
by Zacks Equity Research
Glaxo (GSK) withdraws from the process related to Pfizer's Consumer Health unit. Shingrix gains regulatory approval in Japan and EU.
GlaxoSmithKline Initiates Phase III Combo Study on Benlysta
by Zacks Equity Research
GlaxoSmithKline (GSK) initiates a phase III study evaluating Benlysta in combination with Rituxanin adult patients with systemic lupus erythematosus.
Pfizer's Xtandi Label Expansion Filing Gets Priority Review
by Zacks Equity Research
FDA grants priority review status to Pfizer's(PFE) sNDA to expand the label of Xtandi to include the non-metastatic prostate cancer patient population.
Pharma Stock Roundup: ABBV's Elagolix Meets Study Goal, MRK's Keytruda in Focus
by Zacks Equity Research
Merck gains priority review for Keytruda in advanced cervical cancer, AbbVie's elagolix meets primary endpoint in second phase III study.
J&J's (JNJ) Erdafitinib Gets Breakthrough Therapy Status
by Zacks Equity Research
The breakthrough therapy designation for J&J's (JNJ) erdafitinib was based on efficacy findings from a phase II study, evaluating it in advanced urothelial cancer.
Is GlaxoSmithKline (GSK) a Great Stock for Value Investors?
by Zacks Equity Research
Let's see if GlaxoSmithKline plc (GSK) stock is a good choice for value-oriented investors right now from multiple angles.
Merck's Keytruda Gets Priority Review for Cervical Cancer
by Zacks Equity Research
Merck's (MRK) sBLA for Keytruda to expand its label for the treatment of advanced cervical cancer gets acceptance for priority review by the FDA.
Gilead Announces Positive Data on New HIV Therapy Biktarvy
by Zacks Equity Research
Gilead (GILD) announces encouraging data from a phase III study, on its new HIV therapy, Biktarvy, at the 2018 Conference on Retroviruses and Opportunistic Infections in Boston.
Mylan (MYL) Q4 Earnings Surpass Estimates, Revenues Miss
by Zacks Equity Research
Mylan???s (MYL) mixed Q4 results show earnings beat but revenues miss on pricing pressure and weak EpiPen sales.
5 Reasons Why Pfizer (PFE) Could be a Great Pick in 2018
by Zacks Equity Research
Pfizer's (PFE) outperformance is backed by decent quarterly results, positive news flow and regulatory updates.
Emergent (EBS) Q4 Earnings Beat Estimates, 2018 View Solid
by Zacks Equity Research
Emergent's (EBS) earnings and revenues beat estimates in Q4. The top line also improves year over year on higher product sales.